{
    "clinical_study": {
        "@rank": "124219", 
        "arm_group": {
            "arm_group_label": "Neoadjuvant BKM120", 
            "arm_group_type": "Experimental", 
            "description": "Twenty four men will receive 2 weeks of daily BKM120 prior to having radical prostatectomy"
        }, 
        "brief_summary": {
            "textblock": "This is a phase II, study of BKM120 in patients with high-risk, localized prostate cancer.\n      Eligible patients will be enrolled and scheduled to have an ultrasound-guided biopsy of the\n      prostate to confirm high-risk disease and collect prostate tissue for analysis. Two weeks\n      after the biopsy, patients will begin taking 100 mg/day of BKM120.  BKM120 will be given at\n      this dose level orally once daily for 14 days prior to radical prostatectomy at University\n      of California, San Francisco.  Radical prostatectomy will be performed on the day of the\n      last dose of BKM120 at day 14.  No further drug will be tken after the radical\n      prostatectomy."
        }, 
        "brief_title": "Neoadjuvant BKM120 in High-risk Prostate Cancer", 
        "completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "High Risk Prostate Cancer", 
        "condition_browse": {
            "mesh_term": "Prostatic Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "This is a phase II, prospective, pharmacodynamic study of BKM120 in high-risk, localized\n      prostate cancer. After informed consent and central pathology review of the core prostate\n      biopsy, eligible patients will be enrolled and scheduled to have an ultrasound-guided biopsy\n      of the prostate to confirm high-risk disease and collect tissue for molecular analysis. Two\n      weeks after the biopsy, patients will begin taking 100 mg/day of BKM120.  BKM120 will be\n      given at this dose level orally once daily for 14 days prior to radical prostatectomy at\n      University of California, San Francisco.  Radical prostatectomy will be performed on the day\n      of the last dose of BKM120 at day 14.  No further drug will be administered after radical\n      prostatectomy.\n\n      Up to 24 patients, or 21 evaluable patients, will be enrolled through the Department of\n      Urology or Genitourinary Medical Oncology at the University of California, San Francisco for\n      this pharmacodynamic study. Toxicity will be assessed during BKM120 administration, and will\n      involve a clinic visit on Day 14 \u00b1 2 (i.e. before surgery).  Follow-up with safety\n      evaluations will be at 90 \u00b1 7 days post-operatively and involve a toxicity questionnaire,\n      blood tests, and clinic visit.  Toxicity will be monitored and reported using NCI Common\n      Toxicity Criteria version 4.0 guidelines.\n\n      A patient symptom diary will be distributed to each patient at baseline for symptom\n      self-recording and BKM120 dose self-administration.  In addition, a patient identifier card\n      (wallet-sized) will be distributed to each patient after informed consent and registration.\n      This information will contain the patient's age, study name and number, investigator and\n      study coordinator contact information, and expected adverse events that may be present as a\n      result of BKM120 administration."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "INCLUSION CRITERIA\n\n          1. Histologically confirmed adenocarcinoma of the prostate\n\n          2. Candidate for radical prostatectomy\n\n          3. Prostate cancer with the following pathological characteristics:\n\n        1) Gleason sum > 8 AND at least 2 discrete core biopsies containing a minimum of 20%\n        cancer OR 2) Gleason pattern 4 + 3 = 7 AND greater than 50% of biopsies positive for\n        prostate cancer 4. Age \u2265 18 years 5. ECOG performance status \u00a3 2 6. Ability to take oral\n        medications (capsule must be swallowed with liquid) 7. Adequate bone marrow function as\n        shown by: ANC \u2265 1.5 x 109/L, Platelets \u2265 100 x 109/L, Hgb > 9 g/dL 8. Total calcium\n        (corrected for serum albumin) within normal limits (biphosphonate use for malignant\n        hypercalcemia control is not allowed) 9. Magnesium \u2265 the lower limit of normal 10.\n        Potassium within normal limits for the institution 11. Alanine aminotransferase (ALT) and\n        aspartate aminotransferase (AST) within normal range 12. Serum bilirubin within normal\n        range (or total bilirubin \u2264 3.0 x ULN with direct bilirubin within normal range in\n        patients with well documented Gilbert Syndrome) 13. Serum creatinine \u2264 1.5 x ULN or\n        24-hour clearance \u2265 50 mL/min 14. Serum amylase \u2264 ULN 15. Serum lipase \u2264 ULN 16. Fasting\n        plasma glucose \u2264 120 mg/dL (6.7 mmol/L) 17. INR \u2264 2 18. Men of reproductive potential and\n        their female partners must use highly effective contraception  during treatment, for 5\n        half-lives (8 days) after stopping treatment and for additional 12 weeks (3 months in\n        total after study drug discontinuation) and should not father a child in this period  The\n        highly effective contraception is defined as either:\n\n          1. True abstinence: When this is in line with the preferred and usual lifestyle of the\n             subject. Periodic abstinence (e.g., calendar, ovulation, symptothermal,\n             post-ovulation methods) and withdrawal are not acceptable methods of contraception.\n\n          2. Sterilization:  Female partners have had surgical bilateral oophorectomy (with or\n             without hysterectomy) or tubal ligation at least six weeks ago.  In case of\n             oophorectomy alone, only when the reproductive status of the woman has been confirmed\n             by follow up hormone level assessment.\n\n          3. Male participant sterilization (with the appropriate post-vasectomy documentation of\n             the absence of sperm in the ejaculate).\n\n          4. Use of a combination of any two of the following (a+b):\n\n               1. Female partner with prior placement of an intrauterine device (IUD) or\n                  intrauterine system (IUS)\n\n               2. Barrier methods of contraception: Condom or Occlusive cap (diaphragm or\n                  cervical/vault caps) with spermicidal foam/gel/film/cream/vaginal suppository\n\n                    -  Oral contraception use by female partners, injected or implanted hormonal\n                       methods are not allowed as BKM120 potentially decreases the effectiveness\n                       of hormonal contraceptives.\n\n                    -  Fertile males, defined as all males physiologically capable of conceiving\n                       offspring must use condom during treatment, for 5 T1/2 (8 days) after\n                       stopping treatment and for additional 12 weeks (3 months in total after\n                       study drug discontinuation) and should not father a child in this period.\n\n        19. Ability to understand and the willingness to sign a written informed consent document\n\n        EXCLUSION CRITERIA\n\n          1. Prior treatment with a PI3K inhibitor\n\n          2. Known hypersensitivity to BKM120 or to its excipients\n\n          3. History of another malignancy within 3 years, except cured basal cell carcinoma of\n             the skin\n\n          4. Hormonal therapy with GnRH agonists, GnRH antagonists or high dose biclutamide within\n             1 month of enrollment unless serum testosterone is within normal limits.\n\n          5. Following mood disorders as judged by the investigator and/or symptom management\n             service co-investigator, or as a result of patient's mood assessment questionnaire:\n\n               -  Medically documented history of or active major depressive episode, bipolar\n                  disorder (I or II), obsessive-compulsive disorder, schizophrenia, a history of\n                  suicidal attempt or ideation, or homicidal ideation (immediate risk of doing\n                  harm to others)\n\n               -  Current \u2265 CTCAE grade 3 anxiety\n\n               -  Meets the cut-off score of \u2265 10 in the PHQ-9 or a cut-off of \u2265 15 in the GAD-7\n                  mood scale, respectively, or selects a positive response of \"1, 2, or 3\" to\n                  question number 9 regarding potential for suicidal thoughts in the PHQ-9\n                  (independent of the total score of the PHQ-9) will be excluded from the study\n\n          6. Current diarrhea \u2265 CTCAE grade 2\n\n          7. Active cardiac disease including any of the following:\n\n               -  History of left ventricular ejection fraction (LVEF) < 50% as determined by\n                  Multiple Grated acquisition (MUGA) scan or echocardiogram (ECHO)\n\n               -  QTc > 450 msec on screening ECG (using the QTcF formula)\n\n               -  Angina pectoris that requires the use of anti-anginal medication\n\n               -  History of ventricular arrhythmias except for benign premature ventricular\n                  contractions\n\n               -  Supraventricular and nodal arrhythmias requiring a pacemaker or not controlled\n                  with medication\n\n               -  Conduction abnormality requiring a pacemaker\n\n               -  Valvular disease with documented compromise in cardiac function\n\n               -  Symptomatic pericarditis\n\n          8. History of cardiac dysfunction including any of the following:\n\n               -  Myocardial infarction within the last 6 months, documented by persistent\n                  elevated cardiac enzymes or persistent regional wall abnormalities on assessment\n                  of LVEF function\n\n               -  History of documented congestive heart failure (New York Heart Association\n                  functional classification III-IV)\n\n               -  Documented cardiomyopathy\n\n          9. Poorly controlled diabetes mellitus or active, steroid-induced diabetes mellitus\n\n         10. Other concurrent severe and/or uncontrolled concomitant medical conditions (e.g.,\n             active or uncontrolled infection) that could cause unacceptable safety risks or\n             compromise compliance with the protocol\n\n         11. Impairment of gastrointestinal (GI) function or GI disease that may significantly\n             alter the absorption of BKM120 (e.g., ulcerative diseases, uncontrolled nausea,\n             vomiting, diarrhea, malabsorption syndrome, or small bowel resection). Patients with\n             unresolved diarrhea will be excluded as previously indicated\n\n         12. Treatment with any hematopoietic colony-stimulating growth factors (e.g., G-CSF,\n             GM-CSF) \u2264 2 weeks prior to starting study drug. Erythropoietin or darbepoetin\n             therapy, if initiated at least 2 weeks prior to enrollment, may be continued\n\n         13. Current treatment with medication with a known risk to prolong the QT interval or\n             inducing Torsades de Pointes and the treatment cannot either be discontinued or\n             switched to a different medication prior to starting study drug.  Please refer to\n             section 10.2 for a list of prohibited QT prolonging drugs with risk of Torsades de\n             Pointes.\n\n         14. Current, chronic treatment with steroids or another immunosuppressive agent\n\n             \u2022 Note: Topical applications (e.g. rash), inhaled sprays (e.g. obstructive airways\n             diseases), eye drops or local injections (e.g. intr-articular) are allowed. If a\n             patient stops corticosteroids prior to study participation, a 2-week washout is\n             required.\n\n         15. Taking herbal medications and certain fruits and juices within 7 days prior to\n             starting study drug. Herbal medications include, but are not limited to St. John's\n             wort, Kava, ephedra (ma huang), gingko biloba, dehydroepiandrosterone (DHEA),\n             yohimbe, saw palmetto, and ginseng.  Fruits and juice include the CYP3A inhibitors:\n             Seville oranges, grapefruit, and pomelos.\n\n         16. Current treatment with drugs known to be moderate and strong inhibitors or inducers\n             of isoenzyme CYP3A, and the treatment cannot be discontinued or switched to a\n             different medication prior to starting study drug.  Please refer to Section 10.2 for\n             a list of prohibited inhibitors and inducers of CYP3A (Please note that co-treatment\n             with weak inhibitors of CYP3A is allowed)\n\n         17. Chemotherapy or targeted anticancer therapy \u2264 4 weeks (6 weeks for nitrosourea,\n             antibodies or mitomycin-C) prior to starting study drug\n\n         18. Any continuous or intermittent small molecule therapeutics (excluding monoclonal\n             antibodies) \u2264 5 effective half lives prior to starting study drug or patients who\n             have not recovered from side effects of such therapy\n\n         19. Major surgery \u2264 2 weeks prior to starting study drug or who have not recovered from\n             side effects of such therapy\n\n         20. Current treatment with warfarin sodium or any other coumadin-derivative anticoagulant\n\n         21. Known diagnosis of human immunodeficiency virus (HIV) infection. Testing is not\n             required for participation.\n\n         22. Unable or unwilling to abide by the study protocol or cooperate fully with the\n             investigator"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "85 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "24", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 26, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01695473", 
            "org_study_id": "UCSF CC# 115516"
        }, 
        "intervention": {
            "arm_group_label": "Neoadjuvant BKM120", 
            "description": "Two weeks after confirmatory biopsy, patients will begin taking 100 mg/day of BKM120.  BKM120 will be given at this dose level orally once daily for 14 days prior to radical prostatectomy.  Radical prostatectomy will be performed on the day of the last dose of BKM120 at day 14.  No further drug will be administered after radical prostatectomy.  For unforeseen delays in OR scheduling, up to 7 additional days of BKM120 may be administered prior to surgery.", 
            "intervention_name": "BKM120", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Prostate cancer", 
            "High-risk prostate cancer", 
            "Radical prostatectomy", 
            "BKM120"
        ], 
        "lastchanged_date": "May 15, 2013", 
        "location": {
            "contact": {
                "email": "phillip.febbo@ucsf.edu", 
                "last_name": "Phillip G Febbo, MD", 
                "phone": "415-353-9865"
            }, 
            "contact_backup": {
                "email": "walshp@medicine.ucsf.edu", 
                "last_name": "Paula Dutton", 
                "phone": "415-885-7871"
            }, 
            "facility": {
                "address": {
                    "city": "San Francisco", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "94115"
                }, 
                "name": "UCSF Helen Diller Family Comprehensive Cancer Center"
            }, 
            "investigator": [
                {
                    "last_name": "Phillip G Febbo, MD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Won Kim, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Peter Carroll, MD, MPH", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Maryanne Christoforou, NP", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Laura Dunn, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Lawrence Fong, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Terence Friedlander, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Andrea Harzstark, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Amy Lin, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Michael Rabow, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Eric Small, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Tammy Rodvelt, NP", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Charles Ryan, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Jennifer Schutzman, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Katsuto Shinohara, MD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Pharmacodynamic Study of Pre-prostatectomy BKM120 in Men With High-risk, Localized Prostate Cancer", 
        "overall_contact": {
            "email": "phillip.febbo@ucsf.edu", 
            "last_name": "Phillip G Febbo, MD", 
            "phone": "415-353-9865"
        }, 
        "overall_contact_backup": {
            "email": "walshp@medicine.ucsf.edu", 
            "last_name": "Paula Dutton", 
            "phone": "415-885-7871"
        }, 
        "overall_official": {
            "affiliation": "University of California, San Francisco", 
            "last_name": "Phillip G Febbo, MD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Determine the proportion of men with downstream target inhibition of PI3K in prostate tumor tissue as measured by phosphorylated S6 immunohistochemistry (ICH) when treated with 100 mg/day of BKM120 using paired tumor biopsies from before and after drug administration", 
            "measure": "PI3K inhibition in prostate tumor tissue", 
            "safety_issue": "No", 
            "time_frame": "90-120 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01695473"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of California, San Francisco", 
            "investigator_full_name": "Phillip Febbo", 
            "investigator_title": "UCSF Professor of Medicine and Urology; Leader Prostate Cancer Program", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Determine the proportion of men with downstream target inhibition of PI3K in prostate tumor tissue as measured by 4EBP1 protein phosphorylation immunohistochemistry (IHC) using paired tumor biopsies from before and after drug administration", 
                "measure": "4EBP1 protein", 
                "safety_issue": "No", 
                "time_frame": "90-120 days"
            }, 
            {
                "description": "Evaluate the activity of short term BKM120 administration in prostate cancer as measured in PSA response immediately prior to surgery", 
                "measure": "BKM120 activity", 
                "safety_issue": "No", 
                "time_frame": "90-120 days"
            }, 
            {
                "description": "Determine the proportion of men with downstream target inhibition of PI3K in prostate tumor tissue as measured by AKT protein phosphorylation immunohistochemistry (IHC)", 
                "measure": "AKT protein", 
                "safety_issue": "No", 
                "time_frame": "90-120 days"
            }
        ], 
        "source": "University of California, San Francisco", 
        "sponsors": {
            "collaborator": {
                "agency": "Novartis", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Phillip Febbo", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2013"
    }
}